- Home
- GPMT vs AVTX Comparison
GPMT vs AVTX Comparison
Compare GPMT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPMT
- AVTX
- Stock Information
- Founded
- GPMT 2015
- AVTX 2011
- Country
- GPMT United States
- AVTX United States
- Employees
- GPMT N/A
- AVTX N/A
- Industry
- GPMT Real Estate Investment Trusts
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- GPMT Real Estate
- AVTX Health Care
- Exchange
- GPMT Nasdaq
- AVTX Nasdaq
- Market Cap
- GPMT 122.0M
- AVTX 138.8M
- IPO Year
- GPMT 2017
- AVTX 2015
- Fundamental
- Price
- GPMT $2.75
- AVTX $13.50
- Analyst Decision
- GPMT Buy
- AVTX Strong Buy
- Analyst Count
- GPMT 3
- AVTX 9
- Target Price
- GPMT $3.13
- AVTX $30.14
- AVG Volume (30 Days)
- GPMT 204.3K
- AVTX 451.4K
- Earning Date
- GPMT 11-05-2025
- AVTX 11-06-2025
- Dividend Yield
- GPMT 7.29%
- AVTX N/A
- EPS Growth
- GPMT N/A
- AVTX N/A
- EPS
- GPMT N/A
- AVTX N/A
- Revenue
- GPMT N/A
- AVTX $441,000.00
- Revenue This Year
- GPMT N/A
- AVTX N/A
- Revenue Next Year
- GPMT $26.51
- AVTX N/A
- P/E Ratio
- GPMT N/A
- AVTX N/A
- Revenue Growth
- GPMT N/A
- AVTX N/A
- 52 Week Low
- GPMT $1.61
- AVTX $3.39
- 52 Week High
- GPMT $3.66
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- GPMT 37.65
- AVTX 65.78
- Support Level
- GPMT $2.93
- AVTX $12.41
- Resistance Level
- GPMT $3.03
- AVTX $14.73
- Average True Range (ATR)
- GPMT 0.08
- AVTX 0.94
- MACD
- GPMT -0.04
- AVTX 0.13
- Stochastic Oscillator
- GPMT 0.03
- AVTX 70.97
About GPMT Granite Point Mortgage Trust Inc.
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).